<span id="midArticle_start"/> Transgene SA :
<span id="midArticle_0"/>* Announces positive new results from phase IIb time trialwith TG4010 immunotherapy in non-small cell lung cancer
<span id="midArticle_1"/> <span class="first-article-divide"/>* Says results have been presented at American Society ofClinical Oncology (ASCO) Annual Meeting in Chicago
<span id="midArticle_2"/> <span class="second-article-divide"/>* Data confirms strength of previously reported improvementsin progression-free survival (PFS) and overall survival (OS)
<span id="midArticle_3"/> <span class="third-article-divide"/>* TG4010 has improved response rate and longer duration ofresponse and activity in patients with low PD-L1 expressingtumors, particularly in patients with non-squamous tumorsSource text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Announces positive new results from phase IIb time trialwith TG4010 immunotherapy in non-small cell lung cancer
<span id="midArticle_1"/> <span class="first-article-divide"/>* Says results have been presented at American Society ofClinical Oncology (ASCO) Annual Meeting in Chicago
<span id="midArticle_2"/> <span class="second-article-divide"/>* Data confirms strength of previously reported improvementsin progression-free survival (PFS) and overall survival (OS)
<span id="midArticle_3"/> <span class="third-article-divide"/>* TG4010 has improved response rate and longer duration ofresponse and activity in patients with low PD-L1 expressingtumors, particularly in patients with non-squamous tumorsSource text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1FOoKQs
No comments:
Post a Comment